NCI Opens Wearable Temperature Monitoring Trial to Prevent Severe Cytokine Release Syndrome in Cancer Immunotherapy

References

1. 1.National Cancer Institute. (2024). Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event. ClinicalTrials.gov. NCT07499128. https://clinicaltrials.gov/study/NCT07499128
2. 2.Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. (2018). Cytokine release syndrome. Journal for ImmunoTherapy of Cancer, 6(1), 56. https://doi.org/10.1186/s40425-018-0343-9
3. 3.Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., Go, W. Y., Eldjerou, L., Gardner, R. A., Frey, N., Curran, K. J., Maloney, D. G., Hicks, C., Pasquini, M., Appelbaum, F. R., ... Neelapu, S. S. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25(4), 625-638. https://doi.org/10.1016/j.bbmt.2018.12.758
4. 4.Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., Westin, J., Gulbis, A. M., Loghin, M. E., de Groot, J. F., Adkins, S., Davis, S. E., Rezvani, K., Hwu, P., & Shpall, E. J. (2018). Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nature Reviews Clinical Oncology, 15(1), 47-62. https://doi.org/10.1038/nrclinonc.2017.148
5. 5.Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A. (2014). Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer Journal, 20(2), 119-122. https://doi.org/10.1097/PPO.0000000000000035